H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today. The company's shares closed last Friday at $0.22, close to its 52-week low of $0.19. According to TipRanks.com, Arce is a 4-star analyst with an average return of 4.5% and a 33.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Iterum Therapeutics.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-hold-rating-for-iterum-therapeutics-itrm-2?utm_source=advfn.com&utm_medium=referral